Cboe UK CHF
Novartis AG (NOVNZ.XC)
94.22
+0.69
+(0.74%)
At close: May 2 at 4:19:59 PM GMT+1
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
18,999,000
17,619,000
14,458,000
14,236,000
15,071,000
Investing Cash Flow
-6,284,000
-7,513,000
5,596,000
1,468,000
4,208,000
Financing Cash Flow
-15,126,000
-11,742,000
-14,278,000
-20,562,000
-16,264,000
End Cash Position
7,058,000
11,459,000
13,393,000
7,517,000
12,407,000
Capital Expenditure
-4,152,000
-3,814,000
-2,753,000
-2,239,000
-2,556,000
Issuance of Debt
6,437,000
7,101,000
546,000
252,000
16,000
Repayment of Debt
-3,723,000
-2,711,000
-2,481,000
-2,837,000
-5,987,000
Repurchase of Capital Stock
-9,948,000
-8,331,000
-8,719,000
-10,652,000
-3,057,000
Free Cash Flow
14,847,000
13,805,000
11,705,000
11,997,000
12,515,000
12/31/2021 - 1/23/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade